Contact Information According to MEDVi's website: Email: [email protected] Phone: (323) 690-1564 Physical Address: 131 Continental Dr, Ste 305, Newark, DE 19713 Additional information available at company website
This projection is supported by the broad utility of GLP-1 medications, which not only are effective for weight loss but also improve a range of comorbid conditions associated with obesity, including heart failure, chronic kidney disease, sleep apnea, and fatty liver disease
The trial is listed as active, not recruiting , with a projected primary completion date in February 2026 , with full readouts likely later that year
As with many medications that affect the gastrointestinal system, patients may notice changes in their bowel habits, including alterations in stool colour